Gilde Healthcare Partners awarded European Venture Fundraising of the year - Gilde Healthcare

Gilde Healthcare Partners awarded European Venture Fundraising of the year

February 12, 2008

Utrecht – Gilde Healthcare Partners, a rapidly growing European venture capital firm, has received the Venture Fundraising of the Year Award from the European Venture Capital Journal. The Award was for the successful closing of Gilde Healthcare II (GHC II), its EUR 150 million venture fund, in 2007. The original target for GHC II was EUR 125 million.

GHC II is one of the largest venture funds raised to invest in European healthcare opportunities. GHC II was backed by current investors in Gilde Healthcare Funds, who were joined by a small select group of new investors. Investors were attracted by Gilde Healthcare Partners’ excellent investment track record which has seen it achieve six successful exits in the past two years.
 
Gilde Healthcare Partners invests in strong professional management teams developing therapeutics, diagnostics, medical devices and enabling technologies. Gilde creates significant value for both its investors and the driven entrepreneurs it backs by selectively investing in companies with well thought-out business models. The fund invests at all stages of a company’s development from seed stage to pre-IPO rounds. Gilde’s investments range from EUR 1 million up to EUR 15 million per investee company after all private rounds of financing. 
Founded in 2000, Gilde Healthcare Partners is headquartered in Utrecht, The Netherlands with representatives in London and Madrid. Gilde Healthcare Partners currently has over EUR 275 million (USD 400 million) under management. Gilde is an ambitious builder of healthcare businesses across Europe. Companies that Gilde Healthcare Partners has pro-actively supported span all aspects of healthcare and include Ablynx (Belgium), Agendia (Netherlands), AMT (Netherlands), Ascendis Pharma (Denmark), Chroma Therapeutics (UK), Glycart (Switzerland), Innate Pharma (France), Santaris Pharma (Denmark) and Symphogen (Denmark). For a full list of Gilde’s portfolio companies please visit the website.

Gilde Healthcare II is supported by the European Communities Growth and Employment Initiative, MAP – ETF Start up Facility

Gilde Healthcare company Volta Medical announces positive results from transatlantic trial on AI-assisted ablation for persistent atrial fibrillation

TAILORED-AF randomized controlled trial (RCT) findings demonstrated superiority in freedom from atrial fibrillation (AF) at 12 months from a tailored cardiac ablation guided by artificial intelligence (AI) when compared to pulmonary vein isolation (PVI) alone....
May 21, 2024

Gilde Healthcare co-leads $100M equity financing in Karius

Karius®, Inc., a world leader in genomic diagnostics for infectious disease, today announced it has secured $100 million in Series C funding. The round was co-led by Gilde Healthcare, Khosla Ventures and 5AM Ventures, and...
May 2, 2024

Gilde Healthcare company Ablative Solutions demonstrates Significant Reduction in Blood Pressure meeting its primary endpoint in Pivotal Trial

Ablative Solutions, Inc., announced that primary trial results from the TARGET BPI Pivotal Trial, evaluating alcohol-mediated renal denervation with the Peregrine SystemTM Kit, were presented as a Late-Breaking Clinical Trial at the American College of...
April 11, 2024